Retatrutide, a novel dual-acting glucose-regulated incretin analog, represents TB 500 a significant leap in peptide therapeutics for the management of type 2 sugar disorders and, increasingly, excess adiposity. Unlike many existing treatment interventions, retatrutide merges the actions of a GLP-1 receptor stimulant and a GIP receptor activator, of